Abstract:Lecithin:cholesterol acyltransferase (LCAT) exhibits α-activity on high-density and β-activity on low-density lipoproteins. However, the molecular determinants governing LCAT activation by different apolipoproteins remain elusive. Uncovering these determinants would offer the opportunity to design and explore advanced therapies against dyslipidemias. Here, we have conducted coarse-grained and all-atom molecular dynamics simulations of LCAT with nanodiscs made with α-helical amphiphilic peptides either derived from apolipoproteins A1 and E (apoA1 and apoE) or apoA1 mimetic peptide 22A that was optimized to activate LCAT. This study aims to explore what drives the binding of peptides to our previously identified interaction site in LCAT. We hypothesized that this approach could be used to screen for binding sites of LCAT in different apolipoproteins and would provide insights to differently localized LCAT activities. Our screening approach was able to discriminate apoA1 helixes 4, 6, and 7 as key contributors to the interaction with LCAT supporting the previous research data. The simulations provided detailed molecular determinants driving the interaction with LCAT: the formation of hydrogen bonds or salt bridges between peptides E4 or D4 and LCAT S236 or K238 residues. Additionally, salt bridging between R7 and D73 was observed, depending on the availability of R7. Expanding our investigation to diverse plasma proteins, we detected novel LCAT binding helixes in apoL1, apoB100, and serum amyloid A. Our findings suggest that the same binding determinants, involving E4 or D4 -S236 and R7-D73 interactions, influence LCAT β-activity on low-density lipoproteins, where apoE and or apoB100 are hypothesized to interact with LCAT. Atherosclerotic cardiovascular disease is caused by the accumulation of cholesterol in arteries. A developing class of therapies against it attempt to promote the efficiency of high-density lipoprotein (HDL), which removes cholesterol from peripheral cells. Importantly, this includes cholesterol-laden macrophages, also known as foam cells, present in atherosclerotic lesions. In this context, one strategy focuses on improving the cholesterol carrying capacity of HDL by improving the enzymatic activity of lecithin:cholesterol acyltransferase (LCAT). Although LCAT remodels HDL to accept more cholesterol, it also remodels low-density lipoprotein (LDL), which has an opposite effect to HDL. In other words, LDL brings cholesterol to peripheral cells. We hypothesize that this may be part of the reason why LCAT activation hasn't shown clinical success thus far. In order to investigate this, we must selectively inhibit LCAT's activity on LDL, which in turn requires us to know which amino acids take part in the LCAT-HDL and LCAT-LDL interactions. In this article, we've used molecular dynamics simulations to reveal these amino acids. This information will be useful in the optimization of LCAT and HDL based therapies against atherosclerosis as well as in the design of HDL-like drug delivery systems whose properties are affected by LCAT.

Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models

Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans

Systematic evaluation of lecithin:Cholesterol acyltransferase binding sites in apolipoproteins via peptide based nanodiscs: Regulatory role of charged residues at positions 4 and 7

Rescue of Familial Lecithin:Cholesterol Acyltranferase Deficiency Mutations with an Allosteric Activator

Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.

Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase

Pharmacology of the ACAT inhibitor avasimibe (CI-1011)

Synthetic High-Density Lipoproteins Delivering Liver X Receptor Agonist Prevent Atherogenesis by Enhancing Reverse Cholesterol Transport.

Gliflozins, sucrose and flavonoids are allosteric activators of lecithin:cholesterol acyltransferase

[Expression of Lecithin Cholesterol Acyltransferase And/or Apoa-I Mediated by Recombinant Adeno-Associated Virus in Myogenic Cells].

Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy

40. Correction of Dyslipidemia in Murine and Feline Models of Lipoprotein Lipase Deficiency by Intramuscular Administration of AAV1-LPLS447X

Abstract 15297: Discovery and Preclinical Optimization of Selective ABCA1 Inducers as Multifunctional Therapeutic Candidates

Anti-hypercholesterolemic Effects and a Good Safety Profile of SCM-198 in Animals: from ApoE Knockout Mice to Rhesus Monkeys

Natural Antioxidant‐Based Nanodrug for Atherosclerosis Treatment

A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis

A Novel Mouse Model of Familial Combined Hyperlipidemia and Atherosclerosis.

Depleting LCAT aggravates atherosclerosis in LDLR-deficient hamster with reduced LDL-Cholesterol level

Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio